



Practitioner's Docket No.: 8009-7004-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Elizabeth Shanahan-Prendergast

Ser. No.: 09/254,623

Art Unit: 1642

Filed: July 8, 1999

Examiner: Davis, M.

For: Therapeutic Formulations Containing Venom or Venom Anti-Serum Either Alone or  
in Combination for the Therapeutic Prophylaxis and Therapy of Neoplasms

1411B  
10-6-00

Assistant Commissioner For Patents  
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail addressed to  
Assistant Commissioner for Patents, Washington D.C. 20231,  
on September 19, 2000.

Janet M. Stevens

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In response to the Office Action mailed March 20, 2000, please amend the above-  
identified application as follows:

**In the Claims:**

Please amend claims 1, 6, 12, 16, 38, 58 - 72 as follows:

*f* 1. (Amended) A method of treating neoplasm in a mammal in need of such treatment,  
comprising administering to said mammal a therapeutic agent comprising [venom and/or]  
mammalian, plant or insect anti-serum reactive with at least one Phospholipase A<sub>2</sub> type enzyme.

*B* 2 6. (Amended) A pharmaceutical formulation [containing venom and/or] comprising  
mammalian plant or insect anti-serum to PLA<sub>2</sub> enzyme or part thereof in combination with anti-  
serum to Phospholipase C enzyme or part thereof [or] and/or at least one inhibitory [compounds]  
compound to Phospholipase C for use as a therapeutic agent for the therapy of a neoplastic  
condition in a human or animal.

09/27/2000 CV0111 00000048 09254623

01 FC:202  
02 FC:203  
03 FC:226

117.00 0P  
198.00 0P  
925.00 0P